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DNA-Dependent Acetylation of p53
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The transcription coactivator p300 cannot acetylate native p53 tetramers, thus revealing intrinsic confor-
mational constraints on p300-catalyzed acetylation. Consensus site DNA is an allosteric effector that promotes
acetylation of p53, suggesting that p300 has an undefined conformationally flexible interface within the p53
tetramer. To identify such conformationally responsive p300-binding sites, p300 was subjected to peptide
selection from a phage-peptide display library, a technique that can define novel protein-protein interfaces. The
enriched p300-binding peptides contained a proline repeat (PXXP/PXPXP) motif, and five proline repeat
motifs actually reside within the p53 transactivation domain, suggesting that this region of p53 may harbor the
second p300 contact site. p300 binds in vitro to PXXP-containing peptides derived from the proline repeat
domain, and PXXP-containing peptides inhibit sequence-specific DNA-dependent acetylation of p53, indicat-
ing that p300 docking to both the LXXLL and contiguous PXXP motif in p53 is required for p53 acetylation.
Deletion of the proline repeat motif of p53 prevents DNA-dependent acetylation of p53 by occluding p300 from
the p53-DNA complex. Sequence-specific DNA places an absolute requirement for the proline repeat domain
to drive p53 acetylation in vivo. Chromatin immunoprecipitation was used to show that the proline repeat
deletion mutant p53 is bound to the p21 promoter in vivo, but it is not acetylated, indicating that proline-
directed acetylation of p53 is a post-DNA binding event. The PXXP repeat expands the basic interface of a
p300-targeted transactivation domain, and proline-directed acetylation of p53 at promoters indicates that
p300-mediated acetylation can be highly constrained by substrate conformation in vivo.
The tumor suppressor protein p53 is one of the most well-
studied stress-responsive eukaryotic transcription factors that
function in a damage-induced cell cycle checkpoint pathway.
The biochemical activity of p53 linked to its tumor suppression
function is a sequence-specific DNA binding and transactiva-
tion function that controls the expression of gene products
implicated in cell cycle arrest and apoptosis (39).
p53 has been dissected into functional domains that contrib-
ute to its transcription activity. The central domain of p53
contains the sequence-specific DNA binding domain that is
often mutated in human cancers (31). Regulatory domains at
the amino and carboxyl terminal of p53 modulate protein-
protein interactions and DNA-protein interactions that affect
the rate of p53-dependent transcription. The C terminus of p53
contains a domain whose phosphorylation at Ser315 in vivo by
cyclin-dependent kinases (7) or at Ser392 by CK2/FACT stim-
ulates the DNA-binding activity of p53 (23). The N-terminal
domain of p53 contains the highly conserved BOX-I transacti-
vation domain that directs the binding of p53 to the transcrip-
tional adapter protein p300 (2). Phosphorylation of p53 in the
transactivation domain at Ser15 activates p53 by an ATM-
dependent pathway (37). Adjacent phosphorylation of the p53
activation domain at Thr18 or Ser20 by CHK2 activates p53 (36)
by stabilizing the binding of p300 to p53 (11). Docking of p300
to the Thr18/Ser20 phosphorylated-LXXLL transactivation do-
main of p53 in turn promotes sequence-specific DNA-depen-
dent acetylation in the C-terminal domain of p53, thus stabi-
lizing the p300-p53Ac complex (12). These data highlight the
complementary role of phosphorylation and acetylation in as-
sembling a p53-p300 transcription complex.
The coactivator p300 plays a central role in signal integra-
tion with transcriptional components allowing for gene expres-
sion changes in response to a variety of stimuli (8). Tumor
suppressor proteins like E2F and p53 recruit p300/CBP as their
main coactivators, thus revealing these adapter polypeptides as
key partners in transcription-dependent cancer control. In ad-
dition to the scaffolding role of p300/CBP, a role for the co-
activator family in chromatin remodeling has been identified
via an intrinsic acetyltransferase activity (24). The steady-state
levels of histone acetylation mediated by p300/CBP and antag-
onizing histone deacetylases modulates chromatin remodeling
and the rates of gene expression. Further, since the discovery
that p300/CBP also acetylates nonhistone transcription factors
like p53, E2F, and MyoD (18, 29, 35), most studies have dem-
onstrated that the general role for acetylation appears to be in
the stimulation of sequence-specific DNA binding.
The complex regulation and role of p53 acetylation is begin-
ning to be unraveled (33). The original study using p53 showed
that acetylation stimulates the latent DNA-binding function of
p53 (18), while a later study did not show an effect of acetyla-
tion on activating the latent DNA-binding activity of p53 (14).
We have started to reconstitute the stages in the assembly of
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the p300-p53-DNA transactivation complex in order to further
clarify the regulation and function of p53 acetylation. Such
studies have identified three key stages in the assembly reac-
tion. First, phosphorylation by CHK2 at Thr18 or Ser20 in the
p53 activation domain stabilizes p300 docking to the p53 acti-
vation domain (11) via the IBiD and IHD phosphopeptide
binding domains of p300 (12). Second, this docking of p300 is
essential for sequence-specific DNA-dependent acetylation of
p53, indicating that p53 tetramer acetylation has intrinsic con-
formational constraints in the absence of DNA (12). Third, the
function of acetylation as a post-DNA-binding event is to
clamp the p300-p53AC complex into a very stable state (12).
This clamping of p300-p53 after acetylation is consistent with
cellular data showing that acetylation may function to recruit
coactivator complexes at a promoter (4), presumably through
the Bromo homology domain of p300/CBP which has the po-
tential to bind to acetylated residues (28, 32).
One notable feature of the p300-p53 assembly reaction is the
sequence-specific DNA dependence in p53 acetylation (12),
which is consistent with recent ideas that DNA can function as
an allosteric effector to regulate protein-protein interactions at
a promoter (26). The DNA dependence in p53 acetylation
indicates that conformational restraints are placed on the
p300-catalyzed acetylation reaction through conformationally
flexible motifs on p53. To identify such flexible p300-docking
motifs in p53, combinatorial approaches were used to show
that a second, conformationally flexible p300-binding motif
exists within the proline repeat domain of p53. We show here
that the proline repeat domain can bind directly to p300, that
the proline repeat domain responds to conformational changes
mediated by DNA binding, and that p53 binding to promoter
sites in vivo places an absolute requirement on the proline
repeat domain for acetylation to occur. The identification of a
relatively ubiquitous proline repeat p300-binding transactiva-
tion motif complementing the classic hydrophobic LXXLL
motif highlights an additional layer of combinatorial regulation
of core p300 protein-protein interactions at a promoter.
MATERIALS AND METHODS
Plasmids and constructs. EGFP-PRO was constructed by ligating double-
stranded oligonucleotides encoding amino acids (aa) 64 to 92 of human p53
(EGFP-PRO) into XhoI/XbaI-digested EGFP-C3 plasmid (Clontech). EGFP-
NS, EGFP-BOX-I, EGFP-S20D, p21-Luc, Bax-Luc, pGL3-Basic, PG13-CAT,
MG13-CAT, and CMV-p300 have been described previously (12). Individual
PXXP deletion mutants of p53 were constructed using PCR, and the integrity of
the entire reading frame was confirmed by DNA sequencing. The pCMV-
p53ProAE plasmid (p53PXXP) and baculovirus were gifts from Arnold Levine
(Rockefeller University, New York, N.Y.). pcDNA3.1-p53-6KR was obtained
from Ron Hay (University of St. Andrews, St. Andrews, United Kingdom).
His-p300 baculovirus and all of the p300 deletion constructs used for mapping
the proline repeat binding domain in p300 (see Fig. 2) were reported previously
when the phospho-LXXLL-binding domains of p300 were mapped (12).
Cell culture, transfections, phage display, ELISAs, and Western blots. Tran-
sient transfections into A375 and Saos-2 cells and two-site enzyme-linked im-
munosorbent assays (ELISAs) to measure p53 acetylation, GAL-p300 peptide
binding, and p300-p53 complex stability were carried out as previously described
(12). Full-length p300 and MDM2 were purified as described previously (11).
Sf9-expressed wild-type p53 and p53ProAE (p53PXXP) tetramers were puri-
fied by heparin-Sepharose chromatography as described previously (22). The
liposome-mediated method of transfection was carried out using Lipofectamine
2000 based on the manufacturer’s recommendations. Luciferase activity was
quantified using a luminometer (Fluoroskan Ascent FL), and -galactosidase
activity was quantified using a DIAS microplate reader (Dynatech) at a wave-
length of 420 nm. Primary antibodies included anti-p300 (N15), anti-GAL4DBD
(RK5C1), anti-Bax (N20), anti-hBrg1 (H-88), and anti-TRRAP (T-17) (Santa
Cruz Biotechnology, Inc.). Anti-HisG was supplied by Invitrogen. Anti-MDM2
(2A10), anti-p53 (DO-1), and anti-p53 (ICA-9) were described previously (21).
Anti-acetyl p53 K373/382, anti-acetyl p53 K373, anti-acetylhistone H4 (chroma-
tin immunoprecipitation [ChIP] grade), and anti-acetyllysine were supplied by
Upstate Biotechnology Incorporated. Anti-histone was supplied by Roche Di-
agnostics. Anti-enhanced green fluorescent protein (EGFP) was supplied by
Clontech. Anti-p21 (Ab-1) was supplied by Calbiochem. Horseradish peroxidase-
conjugated secondary antibodies were supplied by DAKO. The phage-peptide
display and biopanning procedure using pure p300 or MDM2 was performed as
previously described (38). Immunoprecipitation of protein complexes was per-
formed as described previously (12).
ChIP. HCT116 (p53/) cells (107) were transfected with the indicated plas-
mids, and after 48 h, the cells were treated with 1% formaldehyde for 30 min at
room temperature on a rocker. The cells were then washed and scraped into 10
ml of phosphate-buffered saline with protease inhibitors. Cells were collected by
a 5-min spin at 1,500  g at 4°C, resuspended in 200 l of ChIP lysis buffer A (5
mM HEPES [pH 7.9], 85 mM KCl, 0.5% [vol/vol] NP-40, 1 protease inhibitor
mixture [PIM]), and incubated on ice for 10 min, giving a crude nuclear fraction.
The pellet was then resuspended in 400 l of ChIP lysis buffer B (1% [wt/vol]
sodium dodecyl sulfate [SDS], 10 mM EDTA, 50 mM Tris-HCl [pH 8.1]) and
incubated on ice for 10 min. The DNA was then sonicated by using a W-385
sonicator (Ultrasonics Inc.) with a microtip and five 10-s bursts at 40% maximum
power to give fragments of approximately 600 bp. Initially, optimum conditions
for sonication were determined by agarose gel analysis after reversing cross-links
and precipitated DNA. Cell debris was removed by spinning at 14,000  g for 10
min at 4°C, and supernatant was transferred to a 15-ml Falcon tube. Approxi-
mately 10% of the lysate was retained as an input control. The remaining lysate
was then diluted 10-fold in 3.6 ml of ChIP IP buffer (0.01% [wt/vol] SDS, 1%
[vol/vol] Triton X-100, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris-HCl [pH
8.0], 5 M trichostatin A, 1 PIM), giving a chromatin solution which was then
precleared with 100 l of protein G beads, which had been preadsorbed with
sonicated salmon sperm DNA (20 g of DNA in Tris-EDTA, 1-mg/ml bovine
serum albumin per 100 l of beads), for 45 min at 45°C on a rotary mixer. Beads
were then collected by centrifugation at 2,000  g, and chromatin solution was
transferred to a fresh Falcon tube. At this stage, the solution was split into three
different microcentrifuge tubes to allow different antibody immunoprecipita-
tions. Each tube was then incubated with 2 g of the desired antibody overnight
at 4°C on a rotating wheel. The immune complexes were then captured with 40
l of protein G beads, prepared as described above, for 1 h at 4°C on a rotating
wheel. The beads were then washed with 1 ml of ChIP wash buffer 1 (0.1%
[wt/vol] SDS, 1% [vol/vol] Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1],
150 mM NaCl), ChIP wash buffer 2 (0.1% [wt/vol] SDS, 1% [vol/vol] Triton
X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.1], 500 mM NaCl), ChIP wash
buffer 3 (0.25 M LiCl, 1% [vol/vol] NP-40, 1% [wt/vol] deoxycholate, 1 mM
EDTA, 10 mM Tris-HCl [pH 8.1]), and finally twice with Tris-EDTA (10 mM
Tris.HCl [pH 8]–1 mM EDTA). The protein-DNA complexes were then eluted
by adding 250 l of ChIP elution buffer (1% SDS–0.1 M NaHCO3) to the beads
and vortexing before incubating at room temperature for 15 min. The eluate was
transferred to a fresh tube, and the elution process was repeated with the beads.
The eluates were then combined, and the cross-links were reversed by adding 20
l of 5 M NaCl and incubating for 4 h at 65°C. After incubation, 10 l of 0.5 M
EDTA (pH 8.0), 20 l of 1 M Tris-HCl (pH 6.8), and 10 l of proteinase K (2
mg/ml) were added and incubated for 1 h at 45°C. The DNA was then recovered
by phenol-chloroform extraction. PCRs were carried out according to the rec-
ommendations of the manufacturer (Qiagen) by using HotStar Taq DNA poly-
merase. To each 50-l reaction mixture, 350 ng of each primer was incorporated,
and titration of template (1, 2, and 5 l) was carried out to verify linearity range.
An input DNA sample was also incorporated to act as a control for the PCRs. For
p21 ChIP and GAPDH PCRs, the cycle conditions were as follows: an initial 10-min
Taq activation step at 95°C followed by 30 cycles of 1 min at 95°C, 1 min at 55°C, and
2 min at 72°C, followed by a final 10-min extension at 72°C. The PCR products were
then run on a 1% agarose gel, and PCR products were quantified using a GeneG-
nome bioimager and accompanying software. The oligonucleotides for ChIP in-
cluded the following: GAPDH (forward, AAAAGCGGGGAGAAAGTAGG; re-
verse, CTAGCCTCCCGGGTTTCTCT) and p21 (forward, CCAGCCCTTGGAT
GGTTT; reverse, GCCTCCTTTCTGTCCTGA).
RESULTS
P300 binds proline repeat polypeptides. The phage-peptide
display technique is a relatively powerful method to identify
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novel protein-binding domains on a polypeptide and to select
for high-affinity peptide ligands under carefully controlled in
vitro conditions. For example, using this approach Shimizu et
al. previously identified a novel MDM2-binding site in the core
domain of p53 that is required for p53 ubiquitination (38), and
an independent study selected peptides from a phage-peptide
library that only bind to the activated conformation of protein
kinase C (1). The enrichment procedure we used involves
presentation of approximately 10 ng of native protein to a
phage-peptide library, and the selection for high-affinity pep-
tides is usually extended to three rounds of binding and elution
in order to develop a peptide consensus site. Two rounds of
selection do not enrich enough to acquire peptides of a similar
sequence, and four rounds of selection give only one sequence
of the highest affinity.
To define the flexible contact site in p53 that mediates DNA-
dependent acetylation by p300, peptides that bind to full-
length p300 protein were selected from a phage-peptide li-
brary. Selection of high-affinity binding phage yielded four
types of related proline repeat peptide consensus motifs: PXX
PXXP, PXXP, PXPXP, and PRLP (where P is proline, R is
arginine, L is leucine, and X is any amino acid) (representative
peptides are shown in Fig. 1A). The sequence ITFPAKPT
NYPY was selected three times, the sequence NFMESLPR
LPMH was selected twice, and the PRLP motif was enriched
in four peptides. The remaining peptides were enriched only
once, and this proportion of duplicate to unique peptides with
a common consensus motif indicates that the three rounds of
selection were optimal for this enrichment of p300-binding
peptides.
As a control to define peptide library integrity, purified
MDM2 was used as bait, since MDM2 and p300 bind to the
same N-terminal transactivation domain of the tumor suppres-
sor protein p53. After three rounds of selection, the MDM2
consensus site FXXXWXXL was isolated (Fig. 1B). This con-
sensus motif matches the amino acid residues involved in con-
tacting MDM2 in the crystal structure of the MDM2-p53 com-
plex (25). The sequence TSFAEYWNLLSG was selected three
times (two are depicted in Fig. 1B), and the remaining 20
sequences (data not shown) were unique apart from the core
FXXXWXXL motif. As the majority of peptides were en-
riched only once, this indicates that the three rounds of selec-
tion were also optimal for acquiring a consensus peptide motif.
Is it relatively surprising that we did not find LXXLL pep-
tides enriched in this selection when using full-length p300,
since many LXXLL motif-binding domains exist in p300, in-
cluding C/H1, C/H3, IHD, and IBiD (Fig. 2C). The former two
LXXLL-binding domains of p300 are histidine-cysteine rich
and have a metal ion stabilizing the structure, while the latter
two homologous LXXLL-binding domains are not necessarily
stabilized by a cofactor. Since the numbers of duplicate PXXP
peptides and unique PXXP peptides are relatively equivalent
(Fig. 1A), the lack of LXXLL peptides enriched cannot be
explained by overselection of proline-rich peptides. This ap-
pears to suggest that (i) LXXLL peptides are not stable in
Escherichia coli or that the phage containing these peptides
grow very slowly; (ii) all four LXXLL-binding domains of p300
are denatured under these conditions; or (iii) the PXXP pep-
tide-binding activity of p300 is dominant in this assay. The lack
of enrichment of LXXLL peptides cannot be due to the dena-
turing of the LXXLL-binding domains of p300, since the pure
protein is active in the LXXLL peptide-binding assay and in
LXXLL-dependent acetylation of p53 (see below). Further,
our preliminary data indicate that, using the minimal IHD
domain of p300 (12) in the phage-peptide selection procedure,
we do in fact acquire peptides with a very high degree of
homology to the LXXLL domain of p53 (L. Finlan and T. R.
Hupp, unpublished data). This indicates that the LXXLL-con-
taining phage-peptides are not toxic to E. coli and/or prevent
phage propagation. Thus, the reason for PXXP enrichment
when using phage-peptide display appears to stem from the
fact that this may be a dominant activity of full-length p300 or
that the p300-PXXP peptide complex is relatively more stable
than LXXLL peptide complexes.
The PXXPXXP, PXXP, PXPXP, and PRLP motifs that
were bound by p300 are actually present in a variety of
LXXLL-containing transcription factors (Fig. 1C) and have
the classic LXXLL motif flanking the PXXP repeat motif (data
not shown). Two of these transcription factors stand out as
relevant to this study: (i) SMAD-4 does not have a LXXLL
activation domain but has an atypical activation domain that
contains a proline-rich activation motif (10), and (ii) p53 has a
proline repeat domain that is required for its transcription
activity (40). However, the function of the polyproline domain
in driving p53 activity is not defined. An in vitro peptide-
binding assay was utilized to demonstrate that p300 could bind
directly to these PXXP repeat domains. P300 bound both
SMAD-4 PXXP repeat domains when increasing levels of the
PXXP motif peptides were added to the binding assay (from
0.01 to 1 ng of peptide) (Fig. 1D, rows 1 and 2 versus the
background of no peptide). All three PXXP-containing do-
mains derived from p53 bound p300 protein (Fig. 1D, rows 3 to
5 versus background of no peptide). Phosphorylation of one
PXXP repeat peptide at Thr81 (JNK site) blocked the stable
binding of p300 (Fig. 1E, row 3 versus rows 1 and 2). This
contrasts with the stabilizing effect of phosphorylation at Ser20
on the LXXLL motif binding to p300 (Fig. 1D, row 6 [BOX-
I-S20P] versus row 7 [unphosphorylated BOX-I]) and high-
lights a difference in the sensitivities of the LXXLL- and
PXXP-binding domains of p300 to phosphate addition.
The two phospho-LXXLL-binding domains of p300 map to
an N-terminal domain named IHD (12) and a C-terminal do-
main named IBiD (27), and mapping of the proline repeat-
binding domain of p300 was carried out by using an identical
assay. An in vitro PXXP peptide pull-down assay was em-
ployed that used p300 miniprotein domains obtained from
HCT116 (p53/) cells transfected with the indicated GAL4-
p300 fusion constructs (Fig. 2A). The p300-Gal4 fusion frag-
ments were incubated with an anti-GAL4 antibody in micro-
titer wells to capture the p300 fragments onto the solid phase,
the corresponding biotinylated peptides (nonphosphorylated
LXXLL peptide from the BOX-I domain of p53, PXXP pep-
tide, or no peptide) were added, and p300-peptide complex
stability was quantitated using streptavidin-horseradish perox-
idase. As a positive control, GAL4 fused to full-length p300
protein bound specifically to the PXXP-containing peptide
relative to the unphosphorylated BOX-I domain of p53
(LXXLL) or no-peptide controls (Fig. 2A, row 2 versus row 1).
The minimal PXXP-binding domains in p300 were fine-
mapped to two distinct regions, one in the N terminus and one
8848 DORNAN ET AL. MOL. CELL. BIOL.
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in the C terminus (Fig. 2C, sites for PXXP contact [SPC-1 and
-2]). The Gal4 fusion p300 miniproteins GAL4-2-337 (Fig. 2A,
row 3) and Gal4-192-504 (Fig. 2A, row 4) bound specifically to
the PXXP-containing peptide. This minimal PXXP-binding
domain (SPC-1) in p300 flanks the N-terminal side of the
peptide recognition domain in the C/H1 and IHD domains
(Fig. 2C). The C-terminal site for PXXP contact was also
mapped using fragments of p300. The Gal4 fusion p300 mini-
protein lacking the IBiD domain, GAL4-1709-1913, bound
significantly to the PXXP peptide (Fig. 2A, row 9). An immu-
noblot of the GAL4 fusion proteins demonstrates equivalent
levels of each p300 miniprotein in each PXXP-binding reaction
(Fig. 2B, lanes 1 to 7). This minimal PXXP-binding domain
(SPC-2) resides between aa 1737 and 1913 (Fig. 2C). In sum-
mary, the PXXP-binding domains of p300 (SPC-1 and SPC-2)
flank the phospho-LXXLL-binding domains (IBiD and IHD)
and the classic C/H1 and C/H3 domains, suggesting that p300
can embrace the p53 substrate over a relatively large interface.
Although the regions of p300 that bind p53 were originally
reported to be within the C/H1 and C/H3 domains (15), more
FIG. 1. Proline repeat peptides bind p300. (A) Identification of novel p300-binding peptide motifs by phage-peptide display. The clones isolated
using full-length recombinant p300 protein as a bait for phage-peptide display are highlighted, with the consensus motifs in grey, and include four
representative subsets: PXXPXXP, PXXP, PRLP, and PXPXP. (B) Control reactions using MDM2. Using MDM2 as bait for phage-peptide
display, clones containing the canonical MDM2-binding motif, FXXXWXXL, were isolated. (C) Sequence alignments of the four proline repeat
motifs found in commonly studied transcription factors. (D and E) p300 binds directly to proline repeat motif peptides. Biotinylated peptides were
used as a target for p300 in a microtiter well pull-down assay containing proline repeat peptide sequences from the aligned Smad4 (PXXPXXP,
rows 1 and 2) and p53 (PXXP, rows 3 to 5) regions (D). As a control, p300 binds to the Ser20 phosphorylated LXXLL motif from the known BOX-I
transactivation domain of p53 (row 6) versus unphosphorylated LXXLL motif (row 7). Phosphovariants of the PXXP domain at Thr81 (JNK site,
rows 1 and 2) or the unphosphorylated PXXP domain of p53 (row 3) were used as ligands (E). The amounts of peptide captured are indicated
(0, 0.01, 0.1, and 1 ng), and the amount of p300 protein bound to the indicated peptide domain was quantitated as RLU by using a peroxidase-
linked secondary-antibody coupled to an anti-p300 antibody.
VOL. 23, 2003 PROLINE REPEAT MOTIF CONSTRAINS p53 ACETYLATION 8849
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FIG. 2. Mapping of the proline repeat binding domain of p300 (SPC-1/2). (A) HCT116 p53/ cells were transfected with 5 g of GAL4 control
(row 1), GAL4-p300 (row 2), or the indicated GAL4-p300 miniproteins derived from the N and C termini of p300 (rows 3 to 9). Lysates were
captured onto the solid phase with an anti-GAL4 antibody, and the indicated biotinylated peptide (1 ng) (PXXP peptide [from p53 aa 55 to 74],
unphosphorylated LXXLL motif [from p53], or no peptide) was added and the amount of peptide bound to p300 protein was quantitated as RLU
by using peroxidase linked to streptavidin. (B) Quantitation of GAL4 fusion protein levels. HCT116 p53/ cells were transfected with 5 g of
GAL4 control (lane 1), GAL4-p300 (lane 2), or the indicated GAL4-p300 miniproteins derived from the N and C termini of p300 (lanes 3 to 9).
Lysates were immunoblotted with an anti-GAL4 antibody. (C) Schematic diagram illustrating the two minimal sites for proline contact (SPC-1 and
SPC-2) relative to other p300 subdomains including C/H1, IHD, C/H3, KIX, Bromo, C/H2, and IBiD. The minimal N-terminal SPC-1 domain (aa
192 to 337) is distinct from the phospho-LXXLL p53-binding domain IHD. The minimal C-terminal SPC-2 domain (aa 1737 to 1913) is distinct
from the IBiD domain and partially overlaps with the C/H3 domain (aa 1653 to 1817).
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recent reconstitution studies have identified two new phospho-
LXXLL-binding domains named IHD (12) and IBiD (27).
With these added to the PXXP-binding domains in p300, there
are at least six domains of p300 that can contact p53 under
various conditions. Although the IHD and IBiD domains may
be higher-affinity binding regions for p53, this does not exclude
a contribution of the C/H1 and C/H3 domains of p300 since it
is not clear how p300 embraces the tetravalent p53 substrate.
For example, for p53 tetramer acetylation to occur there may
be a requirement for one C/H1 domain to bind to one mono-
mer, IHD to bind to another monomer, IBiD to bind to a third
subunit, and a PXXP-binding domain to contact a fourth
monomer. Further, it is possible that the in vitro assay we used
to measure p300 activity unfolds the C/H1 and C/H3 domains,
thus releasing IHD and/or IBiD domains to compensate. The
main assay used to access p300 protein integrity is the docking-
dependent acetyltransferase activity of p300. This purified frac-
tion of p300 is active in histone acetylation, p53-phospho-
LXXLL binding, PXXP-peptide binding, p53 protein binding,
and LXXLL-dependent (docking-dependent) p53 acetylation.
To maintain p300 protein activity and conformation from the
outset, EDTA was not included in the lysis buffers nor was
EDTA included in the GAL4-p300 fusion protein-binding as-
say. However, p53 is purified in buffers containing 0.1 mM
EDTA (22). This amount of EDTA does not disrupt folding of
the p53 tetramer nor does it dissociate zinc from the protein.
When diluted into reaction buffers with purified p300, the final
concentration of EDTA ranges from 1 to 3 M, which is not
known to disrupt the very stable Cys/His structure. Further,
p300-coactivated transcription by p53 in vivo is phospho-
LXXLL dependent (11) and is inhibited by transfected IBID
or IHD domains (12), suggesting that the in vitro character of
p300 reflects its in vivo activity. Thus, it appears that in vitro
and in vivo, the C/H1 or C/H3 domain of p300 contributes to
p53 binding to a lesser extent than does IBiD or IHD. We are
presently developing single, double, triple, and quadruple mu-
tants of C/H1, IHD, C/H3, and IBiD in p300 to determine
which are the major docking domains on p300 for the LXXLL
motif of p53.
Proline repeat peptides inhibit p53 acetylation. The addi-
tion of consensus site DNA to reactions containing p53, p300,
and acetyl-coenzyme A (CoA) stimulates p53 acetylation (12).
Further, docking of p300 to the LXXLL motif of p53 is essen-
tial for DNA-dependent acetylation of p53, thus indicating two
possibly interrelated conformational constraints to p53 tet-
ramer acetylation (12). These two conformational constraints
are released by consensus site DNA and presumably by a
second p300-docking interface. If the proline repeat motif
were in fact the second conformationally sensitive interface
driving p53 acetylation, then there should be a connection
between p300 binding to the proline repeat domain and p53
acetylation. We investigated whether the adjacent PXXP re-
peat motif of p53 was also required for mediating acetylation.
Using the p300 acetylation reaction where acetyl-CoA pro-
motes p53 acetylation in a sequence-specific DNA-dependent
manner (Fig. 3B, lane 2 versus lane 1), the PXXP repeat
peptide was found to be a specific inhibitor of DNA-dependent
acetylation (Fig. 3B, lanes 8 to 10 versus lanes 2 to 6). Histone
acetylation was not affected by the PXXP repeat peptide (Fig.
3D, lanes 5 to 7 versus lanes 1 to 4). In the absence of both
DNA and acetyl-CoA, the PXXP repeat peptide reduced the
stable binding of p300 to p53 (Fig. 3E). Furthermore, the
PXXP repeat peptide attenuated acetylation of p53 in the
complete acetylation reaction when p53 was captured in
ELISA format (Fig. 3F), similar to that seen in the immuno-
blot (Fig. 3B). The PXXP peptide, at concentrations ranging
from 50 to 200 M, is a more potent destabilizer of the p53-
p300 protein complex than is the phospho-LXXLL peptide
(Fig. 3E), and the extent of destabilization mirrors the extent
of inhibition of p53 acetylation (Fig. 3F). These data suggest
that the proline repeat motif is the second interaction site we
were looking for and indicate that p300 contacts two contigu-
ous peptide domains on p53 (LXXLL and PXXP).
There is some apparent inconsistency between the assays we
used to assess p300 binding to PXXP peptides. First, the PXXP
peptides in solution were more effective inhibitors of p300-
catalyzed acetylation than the phospho-LXXLL peptides (Fig.
3F). Consistent with this, PXXP peptides were enriched in
phage-peptide display (Fig. 1A), suggesting that proline repeat
rather than leucine repeat peptides bind better in solution to
p300. Second, both PXXP and phospho-LXXLL peptides dis-
rupt the p53 tetramer-p300 complex (Fig. 3E), indicating that
disruption of one docking interaction prevents the other from
compensating. However, the PXXP peptides bind more poorly
to p300 in the solid-phase ELISA than the phospho-LXXLL
peptide (Fig. 1D), and this assay may underestimate the avidity
of p300 for PXXP peptides. It is possible that the PXXP
peptides are hindered sterically by attachment to the solid
phase and that this attenuates p300-PXXP peptide complex
stability. For example, we found that a phosphospecific mono-
clonal antibody binding to a phosphopeptide can be hindered
by attachment of the peptide to the solid phase but the mono-
clonal antibody can bind when the phosphopeptide is cross-
linked to bovine serum albumin and attached indirectly to the
solid phase (data not shown). Thus, according to the results of
three different assays, the affinities of the PXXP and phospho-
LXXLL peptides for p300 are different: phage-peptide display
suggested that the PXXP peptide-p300 complex is much more
stable than the LXXLL-p300 complex, the ELISA suggested
that the phospho-LXXLL peptide binds better to p300 than
does the PXXP peptide, and the acetylation assay showed that
the PXXP peptides are more effective inhibitors.
To begin to address the significance of the PXXP repeat
domain to p53-dependent transcription, we fused a 30-aa
PXXP repeat peptide (aa 64 to 93) to EGFP for in vivo trans-
fection. The cotransfection of either phosphomimetic LXXLL
(S20D) or PXXP peptide-GFP fusions with the p53 gene at-
tenuated p53 activity from the p21 or bax promoters (Fig. 4A
and B). p300 binding to p53 is required for p53 stabilization
after DNA damage (42), and we investigated whether the
EGFP-LXXLL phosphomimetic peptide or the EGFP-PXXP
peptide could neutralize p300 and destabilize p53 protein in
vivo. Notably, the cotransfection of either LXXLL or PXXP-
EGFP fusions alone did not affect basal p53 protein levels (Fig.
4C, lanes 6 and 8 versus lane 2). However, the cotransfection
of the LXXLL and PXXP-EGFP fusions together induced a
striking decrease in steady-state p53 protein levels (Fig. 4C,
lane 10 versus lane 2). The levels of the EGFP fusions remain
equivalent in each transfection (Fig. 4D, lanes 2, 4, 6, 8, and
10). The cotransfection of LXXLL and PXXP-EGFP fusions
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alone or together was sufficient to attenuate endogenous p21
protein levels (Fig. 4E, lanes 6, 8, and 10 versus lanes 2 and 4),
which is consistent with the data showing that p21-Luc reporter
activity is reduced by the peptides (Fig. 4A). This decrease in
p53 protein steady-state levels by cotransfection of both
LXXLL and PXXP-EGFP fusions is due to proteosome-de-
pendent degradation (Fig. 4F, lane 2 versus lane 1). These data
indicate that although disrupting either of the two p300-dock-
ing sites attenuates p53 activity in cells, disrupting both p300-
binding motifs is required to promote p53 protein degradation.
These in vivo data are consistent with in vitro data showing that
the phospho-LXXLL or PXXP peptides inhibit p53 acetylation
(Fig. 3F).
The effects of the LXXLL and PXXP-GFP fusion proteins
on MDM2-dependent ubiquitination of p53 were also exam-
ined (Fig. 4G). The cotransfection of the indicated EGFP
constructs with His-Ub, MDM2, and p53 demonstrates that
MDM2-dependent ubiquitination of p53 is not affected by the
p300-binding peptides (Fig. 4G, lanes 6 to 8 versus lane 4).
However, there was a marginal increase in p53 ubiquitination
when using the MDM2 peptide inhibitor (BOX-I EGFP fu-
sion) (Fig. 4G, lane 5 versus lane 4). The cotransfection of the
LXXLL and PXXP-EGFP fusion proteins together resulted in
p53 protein destabilization (Fig. 4H, lane 8 versus lanes 6 and
7). The transfected EGFP peptides were expressed at similar
levels (Fig. 4I). Thus, two independent p300-binding domains
(LXXLL and PXXP) are required to stabilize p53 protein.
It is curious that total p53 protein can be destabilized by the
GFP fusion peptides that bind p300 without affecting MDM2-
dependent p53 ubiquitination. Since the PXXP and DLXXLL
GFP fusion peptides do not bind MDM2 in vivo, we expected
few changes in MDM2-dependent monoubiquitination of p53.
The monoubiquitinated p53 was pulled out by using a HIS
pull-down assay, and this pool represents a very small pool of
the total p53 protein. Therefore, the depletion of p53 protein
levels (Fig. 4H) by the p300 binding peptides is more repre-
sentative of the total pool of p53 than the minor proportion of
p53 that is HIS monoubiquitinated. Presumably, therefore, in
this cotransfection system, p53 ubiquitination is uncoupled
from protein degradation.
Proline repeat transactivation motif promotes DNA-depen-
dent acetylation of p53 by p300 in vitro and in vivo. The
mechanism of proline-directed acetylation of p53 was deter-
mined by examining the effects of deleting the proline repeat
domain on p53 acetylation. Sequence-specific DNA-dependent
acetylation was observed with wild-type p53 (Fig. 5B, lane 2
FIG. 3. Proline repeat peptides inhibit DNA-dependent acetylation of p53. (A and B) p300-mediated acetylation of p53 is inhibited by PXXP
peptides. Acetylation reactions using p300 and p53 were carried out with or without acetyl-CoA and with the addition of various concentrations
of peptides (50 to 400 ng): LXXLL peptide (lanes 3 to 6) or the PXXP peptide (lanes 7 to 10; proline repeat derived from p53; aa 55 to 74; see
Fig. 1). Shown are results for total p53 (A) and acetylated p53 (B). (C and D) Histone acetylation is not inhibited by PXXP. Acetylation reactions
contained 1 g of histone H4 as the substrate. Acetylation reactions were carried out with various concentrations of peptides (100 to 400 ng):
LXXLL peptide or PXXP peptide. Shown are results for total histone (C) and acetylated histone (D). (E) Quantitation of p300-p53 complex
stability in the presence of the phospho-LXXLL or PXXP peptide. Acetylation reactions were carried out as described for panels A and B but
without acetyl-CoA and consensus site DNA and with various concentrations of peptides as indicated: BOX-I (LXXLL), Ser20 phospho-LXXLL
(S20-P), or PXXP peptide (concentrations in micromolar). After capturing p53 with the monoclonal antibody ICA-9, the relative levels of p300
bound to p53 was quantified by using an anti-p300 antibody followed by a peroxidase-conjugated secondary antibody coupled to chemilumines-
cence. p300 binding is expressed in RLU. (F) Quantitation of p53 acetylation in the presence of the phospho-LXXLL or PXXP peptide.
Acetylation reactions were carried out as described for panels A and B with acetyl-CoA, consensus site DNA, and various concentrations of
peptides as indicated: BOX-I (LXXLL), Ser20 phospho-LXXLL (S20-P), or PXXP peptide. After capturing total p53 with the monoclonal antibody
ICA-9, the relative levels of acetylation of p53 were normalized to total p53 protein levels by using an anti-p53 polyclonal antibody (CM-1) and
the anti-p53 acetylation polyclonal antibody (RLU).
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FIG. 4. p300-binding peptides attenuate p53 activity and destabilize p53 protein steady-state levels in vivo. (A and B) Competitive inhibition
of p53-dependent transcription by p300-binding peptides. pCMV-p53 (1 g) was cotransfected with the luciferase reporters (1 g of p21-Luc [A]
or bax-Luc [B] and the transfection control [pCMV-Gal] and either the GFP-NS [1 g; control], GFP-LXXLL phosphomimetic [1 g], or
GFP-PXXP [1 g] peptide). The RLU is expressed as a ratio of Luc to the internal transfection control (pCMV-Gal). (C to E) p53 and p21
protein levels are destabilized by cotransfection of GFP fusion p300-binding peptides. pCMV-p53 (1 g) and the indicated GFP fusion construct
(1 g; NS, nonspecific; BOX-I, the MDM2-binding peptide; S20D, the phosphomimetic LXXLL; PRO, proline repeat) and the levels of the
indicated proteins were determined by immunoblotting. (F) Destabilization of p53 by p300 targeting is mediated by the proteosome. Acetyl-Leu-
Leu-norleucine (ALLN) was added for 2 h after transfection of the indicated plasmids for 24 h, and the levels of p53 protein are as indicated. (G
to I) p53 ubiquitination by MDM2 is not altered after cotransfection of GFP fusion p300-binding peptides. pCMV-p53 (1 g), the indicated GFP
fusion construct (1 g), pCMV-MDM2, or pCMV-His-ubiquitin was transfected for 24 h, and the levels of the indicated proteins were determined
by immunoblotting. MDM2-dependent ubiquitinated products were purified using a His pull-down assay, blotted with p53 antibodies, and are
shown in panel G.
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versus lane 1), while the p53PXXP tetramer displayed no acet-
ylation (Fig. 5B, lane 4 versus lane 2). The mixed wild-type
p53/p53PXXP tetramer was also found to be defective in acet-
ylation (Fig. 5B, lane 6 versus lane 2). Thus, despite the fact
that this mixed tetramer had four LXXLL motifs and two
PXXP motifs (six of eight docking motifs), p300 cannot acet-
ylate wild-type p53/p53PXXP, suggesting a dominant negative
effect of proline repeat deletion on p53 conformation. After
incubation of the acetylation reaction mixture in the presence
of nonspecific DNA for 5 h instead of 10 min (12), we could
begin to see p53PXXP tetramer and wild-type p53/p53PXXP
tetramer acetylation in the presence of nonspecific DNA (Fig.
5D, lanes 3 and 5 versus lane 1). The inclusion of consensus
site DNA prevented acetylation of the proline-deleted p53
tetramer and the mixed wild-type p53/p53PXXP tetramer (Fig.
5D, lanes 4 and 6 versus lanes 3 and 5), further indicating that
the DNA-bound conformation of p53 requires the PXXP motif
to mediate acetylation.
The acetylation of p53 in the presence of nonspecific DNA
after 5 h of incubation reflects a reaction with a very low
specific activity and may also reflect changes in p53 conforma-
tion over this time frame. The original acetylation study on p53
(18) demonstrated that bacterially expressed p53 can be acety-
lated, though the stoichiometry of acetylation on p53 protein
was not determined nor was the percentage of p53 in the
folded conformation determined. The folded and unfolded
ratios of recombinant p53 protein can be quantified with
monoclonal antibodies specific for the denatured or unfolded
forms of the protein (20). The p53 protein used in our exper-
iments is derived from insect cells, where the majority of the
protein is folded (22). The enhanced 5-h incubation that re-
sulted in some basal p53 acetylation in the absence of consen-
sus site DNA may be due to the unfolding of the p53 tetramer,
resulting in loss of the conformational constraint on acetyla-
tion (see Fig. 10). The native p53 tetramer is known to
“breathe” in an equilibrium between unfolded and folded
states (9), and this breathing presumably permits weak dock-
ing-independent and DNA-independent acetylation to occur.
How does consensus site DNA prevent p53PXXP tetramer
acetylation? Two potential mechanisms could account for this:
(i) after DNA binding, the p53PXXP tetramer binds p300, but
the acetyltransferase activity cannot engage; or (ii) after DNA
binding, the p53PXXP tetramer changes conformation to pre-
clude p300 binding. To determine whether DNA binding by
FIG. 5. The PXXP transactivation motif of p53 is required for sequence-specific DNA-dependent acetylation by p300. (A and B) The PXXP
motif of p53 is required for DNA-dependent acetylation by p300 in vitro. Human recombinant p53 (lanes 1 to 2), p53PXXP (lanes 3 to 4), or
p53/p53PXXP mixed tetramers (lanes 5 to 6) were purified from insect cells and incubated in the linear range for the enzyme assay (10 min) with
p300 and p53 consensus site oligonucleotide DNA (CON, lanes 2, 4, or 6) or nonspecific DNA (Mut, lanes 1, 3, and 5). Relative acetylation was
quantitated by Western blotting using an anti-p53 acetylation antibody (B) and normalized to total p53 protein by using the monoclonal antibody
DO-1 (A). (C and D) The PXXP motif of p53 is required for DNA-dependent acetylation by p300 in vitro. Details are as described for panels A
and B, except that reactions were carried out for 5 h instead of 10 min. (E to G) The PXXP motif of p53 is required for maximal p300-p53 complex
stability in the presence of consensus site DNA. Insect cell-purified human recombinant P53 (E), p53PXXP (F), or p53/p53PXXP mixed tetramers
(G) were captured onto the solid phase of a microtiter well with the ICA-9 anti-p53 monoclonal antibody, including a titration of p53 consensus
site DNA as indicated in panels 1 to 4 (0, 10, 20, or 40 ng). The captured p53 isoforms were incubated with buffer containing insect cell-expressed
recombinant human p300 protein, and the amount of p300 bound to p53 was quantitated using anti-p300 antibodies. The levels of the p53 protein
isoforms were determined using an anti-p53 antibody and quantitated as the ratio of p300 bound to total p53 by using enhanced chemiluminescence
and expressed as RLU.
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the p53PXXP tetramer prevented p300 binding, we quanti-
tated p300-p53PXXP complex stability in the absence and
presence of consensus site DNA (from 0 to 40 ng) (Fig. 5E to
G). In the absence of consensus site DNA, wild-type p53
bound significantly to p300 (Fig. 5E, column 1) and the p300-
p53 complex was marginally stabilized further by addition of
increasing amounts of consensus site DNA oligonucleotide
(from 10 to 40 ng) (Fig. 5E, columns 2 to 4 versus column 1).
Deletion of the PXXP motif did not prevent p300 from com-
plexing with p53 (Fig. 5F, column 1), presumably due to the
LXXLL activation domain in the tetramer. However,
p53PXXP binding to p300 was completely destabilized by the
addition of consensus site DNA (Fig. 5F, columns 2 to 4 versus
column 1). Further, a mixed p53/p53PXXP tetramer was sim-
ilarly destabilized from p300 by DNA (Fig. 5G, columns 2 to 4
versus column 1), indicating that the PXXP domain on wild-
type p53 could not rescue the p300-p53/p53PXXP complex.
This explains why DNA-complexed p53PXXP cannot be acety-
lated by p53 (Fig. 5B and D), as p300 cannot form an interface
with a DNA-bound p53 tetramer lacking PXXP repeat motifs.
Thus, it is the proline repeat motif that places conformational
constraints on p53 acetylation.
It was important to evaluate the contribution of the PXXP
motif to DNA-dependent acetylation in vivo. We previously
developed an in vivo consensus site DNA-dependent acetyla-
tion assay for p53 (12). After cotransfection of genes encoding
p53 and p53PXXP (Fig. 6A, lanes 1 to 8) along with either
nonspecific or consensus site plasmid DNA, cells were lysed
after 24 h and the transfected p53 protein was assayed for both
in vivo acetylation and binding to endogenous p300 protein.
After immunoprecipitation of transfected p53 protein and im-
munoblotting with acetylation-specific p53 antibodies, consen-
sus site plasmid DNA-dependent acetylation was observed
(Fig. 6B, lane 2 versus lane 1). After immunoprecipitation of
endogenous p300 and immunoblotting with an anti-p53 anti-
body, the amounts of transfected wild-type p53 bound to p300
were similar after the cotransfection of either consensus site or
nonspecific plasmid DNA (Fig. 6C, lane 2 versus lane 1). How-
ever, after immunoprecipitation of endogenous p300 and im-
munoblotting with an anti-acetyl-p53 antibody, only wild-type
p53 cotransfected with consensus site plasmid DNA was acety-
lated (Fig. 6D, lane 2 versus lane 1).
Notably, the converse was observed when the proline dele-
tion mutant, p53PXXP, was used. After immunoprecipitation
of endogenous p300 and immunoblotting with an anti-p53 an-
tibody, the amounts of p53PXXP-p300 complexes were similar
after the cotransfection of either consensus site or nonspecific
plasmid DNA (Fig. 6C, lane 4 versus lane 3). Furthermore,
after cotransfection of p53PXXP with consensus site plasmid
DNA, the p53PXXP in complex with p300 was not acetylated
(Fig. 6D, lane 4 versus lane 2). However, transfection of
p53PXXP with the mutant consensus site supercoiled plasmid
permitted significant acetylation of p53PXXP (Fig. 6D, lane 3
versus lane 1). After immunoprecipitation of transfected
p53PXXP protein and immunoblotting with acetylation-spe-
cific p53 antibodies, acetylation was also observed only in the
presence of nonspecific plasmid DNA (Fig. 6B, lane 3 versus
lane 4). This p300-cataylzed acetylation of p53PXXP in the
absence of consensus site DNA can be seen in vitro with long
incubation times (Fig. 5D, lanes 3 and 5) and further indicates
that in vivo, consensus site DNA places an absolute require-
ment for the proline repeat motif to drive p53 acetylation.
FIG. 6. The PXXP motif of p53 is required for sequence-specific DNA-dependent acetylation by p300 in vivo. pCMV-P53 (lanes 1 and 2),
pCMV-p53PXXP (lanes 3 and 4), pCMV-p53-6KR (lanes 5 and 6; mutated acetylation sites), or pCMV-p5330 (lanes 7 and 8; lacking
acetylation sites) were cotransfected into p53/ cells in the presence of consensus site plasmid DNA (pG13-CAT, lanes 2, 4, 6, and 8) or plasmid
DNA without the consensus site (pMG13-CAT, lanes 1, 3, 5, and 7). (A) The amount of total p53 in each transfection was quantified by direct
immunoblotting with the monoclonal antibody DO-1. (B) To quantitate p53 acetylation in vivo, total p53 protein was immunoprecipitated with a
mixture of ICA-9 and DO-1 monoclonal antibodies and the levels of acetylated p53 were quantitated by immunoblotting with the acetylation-
specific antibody. (C and D) Endogenous P300 protein was immunoprecipitated with an anti-p300 antibody, and levels of total p53 protein isoforms
(C) or acetylated p53 isoforms (D) bound to p300 were quantitated by immunoblotting with either the acetylation-specific antibody or a p53 protein
antibody to normalize to the total p53 protein.
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There is an apparent contradiction in data showing the ef-
fects of consensus site DNA on the stability of the p300-
p53PXXP mutant. While in vitro studies using purified pro-
teins indicated that p53PXXP cannot bind to p300 in the
presence of consensus site DNA, after transfection the p300
still binds the p53PXXP mutant in vivo, though the mutant p53
is not acetylated. It is possible that in vivo cotransfection would
force the interactions of p53PXXP and p300 even in the pres-
ence of transfected consensus site plasmid DNA, since it is
known that p300 can recruit cotransfected proteins into nu-
clear inclusions or particles (16). Further, using purified pro-
teins in vitro, a dose-dependent titration can be better con-
trolled under conditions where the intrinsic stability of the
complex can be assessed. Alternatively, differences in complex
stability and the assay conditions could account for the differ-
ences. The solid-phase ELISA used to demonstrate that DNA
prevents formation of a stable complex between p300 and
p53PXXP involves incubations with primary and secondary
antibodies with washings over a 150-min time period, while the
immunoprecipitation from cells involves quick washing times
of only 15 min. The longer washing times in the ELISA would
ensure that weakly bound p300-p53PXXP complexes were not
detected. This may be the most likely explanation for the
discrepancy, since basal p53 acetylation by p300 in the pres-
ence of nonspecific DNA results in destabilization of the p300-
p53 complex, while p53 acetylation by p300 in the presence of
consensus site DNA results in stabilization of the p300-p53
complex (12). Thus, deletion of the PXXP domain may prevent
p53 acetylation when the tetramer is DNA bound, most likely
by increasing the off-rate rather than decreasing the on-rate for
p300.
Deletion of a single PXXP motif attenuates p53 activity in
vivo. Presumably, since p53PXXP cannot be acetylated by p300
when bound to consensus site DNA in vitro or in vivo, the
proline deletion mutant should be inert as a transcription fac-
tor in vivo. Saos-2 (p53/) cells were cotransfected with p53
or p53PXXP genes with or without p300 and the corresponding
p53-dependent luciferase reporter constructs (p21 or bax).
p53-dependent transactivation of the p21 and bax promoters
was attenuated by deletion of the PXXP domain of p53 (Fig.
7A and C, lanes 4 versus lanes 3) despite the similarity in
expression levels of the wild-type and mutant p53 proteins
(Fig. 7B and D, lanes 4 versus lanes 3). The p53PXXP mutant
failed to synergize with p300 protein, and its activity was in-
hibited on the p21 and Bax promoters relative to that of wild-
type p53 (Fig. 7A and C, lanes 6 versus lanes 5). Since the
nature of this transcription assay depends on reporter con-
structs, which have not necessarily been processed with eukary-
otic chromatin assembly proteins and subsequent chromatin
remodeling enzymes, the response from the endogenous p21
and bax promoters was normalized by Western blotting of
endogenous proteins. Induction of p21 and Bax proteins was
reduced after transfection of the p53PXXP mutant relative to
what was seen with wild-type p53 (Fig. 7B and D, lanes 3 and
5 versus lanes 4 and 6).
There are three PXXP repeats and one PXPXP motif in the
p53 activation domain from amino acids 71 to 90 (Fig. 7E), and
we evaluated whether deletion of any proline repeat motif
alters p53 activity and steady-state levels. Deletion mutants
of each PXXP motif produced the recombinant proteins
p5371-75, p5376-80, p5381-85, and p5386-90, and any one of
these PXXP motif mutants attenuated p53-dependent tran-
scription from the p21 reporter (Fig. 7F) and failed to induce
endogenous p21 protein (Fig. 7I). Further, although the
p5372-75, p5381-85, and p5386-90 proteins were expressed at
levels similar to that of wild-type p53 protein, p5376-80 was
expressed at very low levels (Fig. 7G). p5376-80 protein was
degraded by a proteosome-dependent pathway (Fig. 7H, lane 7
versus lane 6). A titration of lower amounts of p53 DNA in the
transfection also revealed that p5381-85 was expressed at very
low levels (data not shown), indicating that the core proline
repeat region, 76-APAAPTPAAP-85 containing the JNK
phosphorylation site, is a major determinant of p53 protein
steady-state levels. However, sites outside this core (aa 76 to
85) proline repeat region are likely to be important under
differing conditions, since the Pro72-Arg72 polymorphism also
has reduced specific activity under the conditions described
above (data not shown).
p53 acetylation in vivo is a post-DNA-binding event. The
role of the C-terminal domain of p53 is twofold. It functions as
a negative regulatory domain whose phosphorylation stimu-
lates in vitro and in vivo the specific DNA-binding function of
p53 (7, 23). The molecular basis for p53 protein latency re-
quires the C-terminal domain to destabilize and unfold the
core DNA-binding domain by allosteric effects (5), suggesting
that p53 is part of a growing group of regulatory proteins that
are native and unfolded in the absence of posttranslational
modification (13). Phosphorylation of p53 in the C-terminal
domain neutralizes the destabilizing effect of the C terminus
on the core domain of p53 and maintains p53 conformation
and activity (30).
The C-terminal domain of p53 also functions as a positive
regulatory domain that is acetylated and that recruits coacti-
vator complexes (4, 14). A molecular explanation for why acet-
ylation recruits coactivators may be found in the ability of
acetyl-CoA to stabilize the p300-p53AC complex in the pres-
ence of consensus site DNA (12). Thus, although the role for
acetylation of p53 remains relatively unclear (33), two comple-
mentary models are emerging. First, when “latent” fractions of
p53 are used, acetylation can stimulate the DNA-binding ac-
tivity of p53 by neutralizing basic residues implicated in non-
specific DNA binding (18). Second, when “kinase-activated”
p53 protein is used, acetylation is a post-DNA-binding event
and its role is to stabilize the p300-p53 AC complex (12). The
proline repeat deletion mutant of p53 can be used to investi-
gate which of these two models is favored in vivo. This relies on
our observation that p53PXXP is acetylated in vivo in the
absence of consensus site DNA, but p53PXXP cannot be acety-
lated in vivo in the presence of consensus site DNA (Fig. 6). If
p53PXXP was acetylated in vivo before p21 promoter binding,
then acetylated p53PXXP should be detected at the p21 pro-
moter by ChIP. However, if p53PXXP is acetylated only after
DNA binding, then because the p53PXXP-DNA complex can-
not bind stably to p300 (Fig. 5), there should be no acetylated
p53PXXP cross-linked to the p21 promoter.
Transfection of p53 and two p53 mutants (PXXP deletion
and the acetylation-defective mutant 6KR) into cells followed
by formaldehyde cross-linking of protein-DNA complexes, im-
munoprecipitation of sonicated protein-DNA complexes, and
PCR amplification with p21- (Fig. 8, bottom panel) and
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FIG. 7. Deletion of a single PXXP motif attenuates p53 activity in vivo. (A to D) Deletion of the entire proline repeat domain inhibits p53.
The transactivation activity of p53 and p53PXXP on the p21 (A) and bax (C) luciferase reporter promoters (RLU) is expressed as the ratio of
p21-Luc or bax-Luc to the internal transfection control (pCMV-Gal). Expression levels of transfected p53 forms and endogenous target gene
products are shown in panels B and D as follows: (B) transfected p53 protein (lanes 3 and 5) or p53PXXP protein (lanes 4 and 6) and endogenous
p21 protein and (D) transfected p53 protein (lanes 3 and 5) or p53PXXP protein (lanes 4 and 6) and endogenous Bax protein were quantitated
by Western blotting with an anti-p53, anti-p21, or anti-Bax protein antibody and enhanced chemiluminescence. In each transfection, 1 g of
pCMV-p53 or pCMV-p53PXXP alone or with 5 g of pCMV-p300 was added as indicated. (E) Map of the clustered PXXP repeat motifs in
the N-terminal activation domain of p53 and site of the PXXP deletions used in this study. (F) The transactivation activity of p53 and individual
p53PXXP deletion mutants on the p21 luciferase reporter promoter (RLU) is expressed as a ratio of p21-Luc to the internal transfection control
(pCMV-Gal). (G and I) Expression levels of transfected p53PXXP deletion mutant p53 proteins (G) and endogenous p21 protein (I) were
quantified by immunoblotting. (H) The unstable PXXP deletion mutant (76-80) was stabilized by ALLN. Twenty-four hours after transfection of
p5376-80, ALLN was added for 2 h prior to harvesting of the cells and p53 was blotted with DO-1 monoclonal antibody.
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GAPDH-specific primers after reversing the chemical cross-
link demonstrated a unique requirement for PXXP in promot-
ing p53 acetylation at the p21 promoter. Using cell lysates
transfected with the wild-type p53 gene (Fig. 8, lanes 6) or
vector-only control (Fig. 8, lanes 5), immunoprecipitation of
p300 (Fig. 8A) resulted in the coprecipitation and PCR am-
plification of the p21 promoter (Fig. 8A, lane 6 [34 relative
luciferase units {RLU}] versus lane 5 [0.8 RLU]). Further,
immunoprecipitation of p53 resulted in the coprecipitation and
PCR amplification of the p21 promoter (Fig. 8B, lane 6 [117
RLU] versus lane 5 [0.5 RLU]). The p53 bound was acetylated,
since immunoprecipitation with acetyl-p53 antibodies resulted
in the coprecipitation and PCR amplification of the p21 pro-
moter (Fig. 8C, lane 6 [62 RLU] versus lane 5 [0.5 RLU]). As
a PCR control for each amplification, GAPDH showed equiv-
alent background levels ranging from 0.5 to 0.7 RLU (Fig. 8A
to C, GAPDH panels).
The key question addressed next was whether deletion of
FIG. 8. The PXXP motif is required to acetylate p53 at the p21 promoter in vivo. HCT116 p53/ cells were transfected with various p53 pCMV
DNAs encoding p53 (lanes 2 and 6), p53PXXP (lanes 3 and 7), and the nonacetylatable mutant, p53-6KR (lanes 4 and 8). Following transfection
of the indicated construct, cross-linking of protein-DNA complexes with formaldehyde, immunoprecipitation, and processing of the samples as
described in Materials and Methods, the released DNA was PCR amplified using primers to the p21 promoter (as indicated in the bottom panel)
or GAPDH promoter. The immunoprecipitation was carried out with antibodies specific for p300 (A), p53 (B), and acetylated p53 (C). The data
are plotted as input DNA or as immunoprecipitated DNA. Quantitation of the bioluminescence is depicted below each lane. Controls include
DNA amplified in reactions processed from cells without antibody in the immunoprecipitation reaction (lane 9) or with vector control only (lanes
1 and 5). The diagram at top depicts the region of the p21 promoter that was focused onto isolate p53-bound transcription complexes.
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p53’s PXXP motif prevents it from being acetylated at pro-
moter sites in vivo. Using cell lysates transfected with the
p53PXXP gene (Fig. 8, lanes 7) or vector-only control (Fig. 8,
lanes 5), immunoprecipitation of p53PXXP resulted in the
coprecipitation and PCR amplification of the p21 promoter
(Fig. 8B, lane 7 [55 RLU] versus lane 5 [0.5 RLU]), indicating
that a relatively large amount of p53PXXP protein is chroma-
tin bound. However, the p53PXXP bound was not acetylated,
since immunoprecipitation with acetyl-p53 antibodies did not
result in the coprecipitation and PCR amplification of the p21
promoter (Fig. 8C, lane 7 [0.8 RLU] versus lane 5 [0.5 RLU]).
This absence of acetylation can be explained by the inability of
p53PXXP in complex with DNA to bind to p300 (Fig. 5).
Similar data were obtained using ChIP from the bax promoter
(data not shown). Thus, p53PXXP is not acetylated before
DNA binding in vivo, confining acetylation of p53 in vivo to a
proline-driven post-DNA-binding event. These data indicate
that the proline deletion mutant behaves like an acetylation
mutant, consistent with the sequence-specific DNA depen-
dence in proline-directed acetylation.
We evaluated whether the proline repeat domain can influ-
ence the recruitment of additional transcription factors impli-
cated in chromatin remodeling and activation of gene expres-
sion (Fig. 9). Using cell lysates transfected with the wild-type
p53 gene (Fig. 9, lanes 6) or vector-only control (Fig. 9, lanes
5), immunoprecipitation of TRRAP (Fig. 9A) resulted in the
coprecipitation and PCR amplification of the p21 promoter
(Fig. 9A, lane 6 [35 RLU] versus lane 5 [8 RLU]). Further-
more, immunoprecipitation of BRG-1 resulted in the copre-
cipitation and PCR amplification of the p21 promoter (Fig. 9B,
lane 6 [59 RLU] versus lane 5 [8 RLU]). Also, enhancement of
histone acetylation was p53 dependent, since immunoprecipi-
tation with acetylhistone antibodies resulted in the coprecipi-
tation and PCR amplification of the p21 promoter (Fig. 9C,
lane 6 [210 RLU] versus lane 5 [60 RLU]). In contrast to
TRRAP and BRG-1 recruitment when wild-type p53 was used,
p53PXXP was unable to recruit a significant amount of BRG-1
or TRRAP. Using cell lysates transfected with the p53PXXP
gene (Fig. 9, lanes 7), the use of antibodies to TRRAP, BRG-1,
or acetylhistone failed to immunoprecipitate the p21 promoter
(Fig. 9A to C, lanes 7 versus lanes 5 and 6).
DISCUSSION
Regulation of eukaryotic gene expression is a dynamic pro-
cess regulated by signal transduction networks that assemble
and disassemble a variety of protein-protein machines. Char-
acterizing these fundamental protein-protein interactions and
their regulation will provide a molecular basis for understand-
ing how the control of gene expression is linked to biological
pathways such as differentiation, development, and cell cycle
control. The coactivator p300 plays a central role in signal
integration with transcriptional components, allowing for gene
expression changes in response to a variety of stimuli (8).
Understanding the mechanism whereby p300 and p53 cooper-
ate as tumor suppressors will shed light on mechanisms that
modulate cancer progression.
One key molecular stage in the cooperation between these
two proteins links sequence-specific DNA binding by p53 and
acetyltransferase activity of p300 (12). Conformational re-
straints on p53 acetylation by p300 are overcome by p53 bind-
ing to its consensus site DNA (Fig. 10). DNA-dependent acet-
ylation of p53 requires p300 docking to the LXXLL domain of
p53 through at least two subdomains in p300, named IHD and
IBiD (12). Importantly, however, the ability of consensus site
DNA to override conformational restraints on p53 acetylation
by p300 suggested to us that p300 contacts an undefined con-
formationally sensitive interaction site on p53. Such a model is
supported by nuclear magnetic resonance studies showing that
the surface of p53 changes conformation when in complex with
consensus site DNA (34). This has led to our search for a
second, conformationally sensitive domain on p53 that binds
p300 and led to the identification of the PXXP repeat domain
as the flexible motif driving sequence-specific DNA-dependent
acetylation of p53. The direct interaction of the proline repeat
motif of p53 with p300 is consistent with the importance of the
proline repeat domain for p53 activity (3, 40). However, we
show an absolute requirement for the proline repeat motif on
p53 activity from transfected p21 or bax reporter templates,
while other studies have shown that p53PXXP can be active
from transfected p21 reporter templates (3).
There have been other molecular studies on proteins that
interact with the proline repeat domain of p53, but none of
these proteins explains the direct contribution of the PXXP
domain to stress-activated transcription. Deletion of the pro-
line repeat domain of p53 sensitizes p53 to MDM2-dependent
degradation (6), presumably because this deletion releases p53
FIG. 9. The PXXP motif is required to recruit TRRAP and BRG-1
to the p21 promoter in vivo. HCT116 p53/ cells were transfected
with various p53 pCMV DNAs encoding p53 (lanes 2 and 6), p53PXXP
(lanes 3 and 7), and the nonacetylatable mutant, p53-6KR (lanes 4 and
8). Following transfection of the indicated construct, cross-linking of
protein-DNA complexes with formaldehyde, immunoprecipitation,
and processing of the samples as described in Materials and Methods,
the released DNA was PCR amplified using primers to the p21 pro-
moter (as indicated in the bottom panel) or GAPDH promoter. The
immunoprecipitation was carried out with antibodies specific for
TRRAP (A), BRG-1 (B), and acetylated histone H4 (C). The data are
plotted as input DNA or as immunoprecipitated DNA. Quantitation of
the bioluminescence is depicted below each lane. Controls include
DNA amplified in reactions processed from cells without antibody in
the immunoprecipitation reaction (lane 9) or with vector control only
(lanes 1 and 5).
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from a “stable” partner protein. The key PXXP-binding pro-
tein that stabilizes p53 appears to be p300 based on four
criteria. First, p300 is essential for stabilizing p53 in response
to DNA damage (42). Second, p300 has an intrinsic proline
repeat-binding activity (Fig. 1). Third, proline repeat peptides
inhibit sequence-specific DNA-dependent p53 acetylation
(Fig. 3). Fourth, the LXXLL and PXXP-GFP fusion peptides
can together destabilize p53 in vivo (Fig. 4). These latter data
are inconsistent with a role for p300 in degrading p53 (17),
unless the sequestration of the PXXP- and LXXLL-binding
domains of p300 by the LXXLL and PXXP-GFP fusion pep-
tides frees up alternate domains in p300 to degrade p53 pro-
tein. Other proteins can bind to the PXXP domain, including
histone deacetylases and proline isomerases. Histone deacety-
lase binding to the PXXP domain switches on the transrepres-
sion function of p53 (43), which is activated in response to
hypoxia, thus indicating a fundamental difference between
classic DNA damage and oxygen deprivation. It may be that
the energy limitations in cells orchestrating a p53 response in
cells undergoing anaerobic metabolism induce a more passive
switch-off of gene expression, rather than the more energeti-
cally demanding DNA damage response. The ability of proline
isomerase to stimulate p53 identifies another proline-related
modifier of p53 (41). It will be interesting in the future to
examine whether proline isomerases or hydroxylases antago-
nize or synergize with p300 and affect DNA-dependent acety-
lation of p53.
In summary, a direct function for the proline domain in
mediating the transactivation function of p53 was identified:
the PXXP motif binds p300. There are therefore two distinct
motifs (LXXLL and PXXP) in p53 that bind directly to p300
and that are required for p300-catalyzed acetylation. The ubiq-
uity of the PXXP domain in many transcription factors (Fig. 1)
flanking the classic LXXLL motif expands on the core p300-
activation motifs. Our preliminary data indicate that proteins
known to bind p300 and having both the LXXLL and PXXP
motifs, including IRF-3 and E-KLF, do in fact require both
motifs for maximal transcription activity (data not shown). The
intrinsic conformational constraints on native, folded, p53 tet-
ramer acetylation by p300 can be overcome after p53 DNA
binding via p300 contacting two transactivation domains in p53
(Fig. 10). This built-in restraint presumably ensures that acet-
ylation of p53 only occurs at promoters in vivo and reveals an
allosteric role for DNA in controlling protein-protein interac-
FIG. 10. DNA induces a conformational change that mediates proline-directed p53 acetylation by p300. (A) In the absence of DNA, p300 can
dock to the p53 tetramer via LXXLL and PXXP binding, but conformational constraints in the native p53 tetramer prevent acetylation.
(B) Sequence-specific DNA binding changes the conformation of p53 (34), thus permitting acetylation to occur in a PXXP-dependent manner.
Thus, DNA binding does not change p300 binding as much as it activates p53 acetylation, suggesting that in the DNA-free state the C terminus
of p53 is cryptic with respect to acetylation. (C) When the PXXP domain is deleted, p300 cannot acetylate DNA-bound p53PXXP due to the
inability of p300 to form stable contacts with the p53PXXP tetramer. However, the p53PXXP tetramer can be acetylated by p300 in the absence
of DNA, with the proline deletion essentially converting the p53PXXP tetramer to a histone-like substrate which can be acetylated in a
docking-independent and DNA-independent manner. These latter data also suggest that DNA binding creates a specific interface in p53 for p300
and that the PXXP domain forms an integral part of this interface. Thus, both the PXXP/LXXLL domains and the C-terminal acetylation motif
act concertedly after DNA binding to permit p300-catalyzed acetylation. There is a precedent for the C-terminal acetylation domain of p53 being
cryptic in the DNA-free state. The p300 acetylation sites in p53 are within the epitope for monoclonal antibody PAb421. When p53 is DNA free,
the PAb421 epitope is cryptic and DNA binding exposes the epitope. This led to the postulation that long-range allosteric effects mediate DNA
binding by p53 (19). The cryptic nature of the p53 acetylation motif in the DNA-free conformation of p53 builds into the tetramer an intrinsic
negative regulatory mechanism to prevent acetylation until the tetramer is promoter bound.
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tions at a promoter (26). The fact that protein kinases and
proline isomerases modify the core LXXLL and PXXP trans-
activation domains of p53 identifies signal transduction path-
ways, like CHK2 and proline isomerase, that stimulate p300
coactivated p53-dependent transcription. Furthermore, the re-
alization that many transcription factors have LXXLL motifs
contiguous to PXXP motifs expands our understanding of the
basal p300 activation domain interactions at a promoter that
may scaffold, bridge, or mediate the recruitment of multipro-
tein complexes at promoters in vivo.
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